Where does Claire Leurent work?

Claire Leurent is Managing Director at AbbVie.

What check size does Claire Leurent write?

Claire Leurent typically writes checks of $100K – $5M.

Where did Claire Leurent go to school?

Claire Leurent studied at MIT Sloan School of Management (Master of Business Administration (MBA), Business Administration and Management); Pierre and Marie Curie University (Certification in CNS Pharmacology); Université Louis Pasteur (Strasbourg I) (PhD, Molecular and Cellular Biology).

Claire Leurent

Investor

Managing Director at AbbVie

Boston, Massachusetts

Writes $100K – $5M checks · typically $1.5M

Find your path to Claire

709 people in our graph share verified history with Claire — schools, employers, funds. One of them is your warm intro.

BirgitteunlockedClaire: together at MIT Sloan School of Management (2014)

×5Claire: together at Johnson & Johnson

×2Claire: together at MIT Sloan School of Management

Claire: together at Vor Biopharma

About

Claire Leurent pairs drug-development experience at Pfizer and Wyeth with cross-institutional venture investing at Samsung, J&J and the NIH, and—while teaching strategy at Northeastern—creates custom deal structures across stages.

Invests in

AI & Machine LearningBiotechData & InfrastructureHealthtech

Experience

AbbVie VenturesManaging Directorcurrent2024 — present
The National Institutes of HealthEntrepreneur in Residence2023 — 2024Bethesda, Maryland, United States
Johnson & JohnsonPrincipal, Venture Investments @ JJDC2019 — 2023
Locus Biosciences, Inc.Board Observer2022
POINT BiopharmaInvestor2021 — 2022
PaigeInvestor2021 — 2022New York City Metropolitan Area
CuraSen Therapeutics, Inc.Board Observer2020 — 2022
X-Vax Technology, Inc.Board Observer2020 — 2022
Vor BiopharmaBoard Observer2019 — 2020
Samsung Venture InvestmentManaging Director2018 — 2019Greater Boston Area
Samsung Venture InvestmentBio Sector Investment Director - Samsung Ventures America2017 — 2019
Digital AssetInvestor2019
Adicet Bio, IncInvestor2019
WelldocBoard Observer2019
Pillo HealthBoard Observer2019Boston, Massachusetts
PfizerDirector - Neuroscience Clinical Research2010 — 2017Cambridge, Massachusetts
PfizerSenior Clinical Scientist2004 — 2010
Forenap PharmaProject Manager2003 — 2004
IGBMC - Institut de Génétique et de Biologie Moléculaire - Strasbourg-Illkirch/FrancePhD1999 — 2003

Skills & more

Neuroscience99Pharmaceutical Industry99Clinical Research99Life Sciences98Biotechnology83Clinical Development82Drug Development74Clinical Trials63Drug Discovery51Pharmacology34Molecular Biology29Lifesciences24

+12 more

GCPOncologyRegulatory AffairsBusiness DevelopmentRegulatory SubmissionsTherapeutic AreasImmunologyFDANeurologyMentoringINDVaccines

From Claire's professional profile.

Colleagues at AbbVie

Anke Reichardt

Investor at AbbVie

Azurii Collier

Commercial Advisor at 2Flo Ventures

Christian Schubert

Head of AbbVie Ventures at AbbVie

Christina Vorvis

Director at AbbVie

Donmienne Leung

Director II, Head of AbbVie Ventures Europe at AbbVie

Doug Faunce

Executive Director at AbbVie

Joachim Vogt

Director at AbbVie

John Ballew

Senior Associate at JDRF T1D Fund

Frequently asked questions

Who is Claire Leurent?: Claire Leurent pairs drug-development experience at Pfizer and Wyeth with cross-institutional venture investing at Samsung, J&J and the NIH, and—while teaching strategy at Northeastern—creates custom deal structures across stages.
Where does Claire Leurent work?: Claire Leurent is Managing Director at AbbVie.
What does Claire Leurent invest in?: Claire Leurent invests in AI & Machine Learning, Biotech, Data & Infrastructure, Healthtech.
What check size does Claire Leurent write?: Claire Leurent typically writes checks of $100K – $5M.
Where did Claire Leurent go to school?: Claire Leurent studied at MIT Sloan School of Management (Master of Business Administration (MBA), Business Administration and Management); Pierre and Marie Curie University (Certification in CNS Pharmacology); Université Louis Pasteur (Strasbourg I) (PhD, Molecular and Cellular Biology).